JX11502MA

DRUG2 trials

Sponsors

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Conditions

Schizophrenia

Phase 1

A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

Zhejiang Jingxin Pharmaceutical Co., Ltd.Schizophrenia

Start: 2020-01-04End: 2022-02-28Target: 58Updated: 2022-02-10

A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.

CompletedNCT06356389

Zhejiang Jingxin Pharmaceutical Co., Ltd.Schizophrenia

Start: 2022-03-02End: 2023-01-28Updated: 2024-04-10

Related Papers

Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration

Expert Opinion on Investigational Drugs2023-12-06